This contract expires in 18 days (Jun 30, 2026).
MAPP BIOPHARMACEUTICAL, INC. - DEVELOPMENT OF A PAN-BOTULINUM NEUROTOXIN MEDICAL COUNTERMEASURE
Key Details
Description
DEVELOPMENT OF A PAN-BOTULINUM NEUROTOXIN MEDICAL COUNTERMEASURE
Context & Analysis
On Feb 13, 2026, Department of Health and Human Services obligated $16,413,163 to MAPP BIOPHARMACEUTICAL, INC. for development of a pan-botulinum neurotoxin medical countermeasure. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a cost plus fixed fee contract. Competition extent: full and open competition with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in SAN DIEGO, CA. The contract is scheduled through Jun 30, 2026 — approximately 1 month remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Contractor Information
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.